MMI’s Symani surgical system received de novo clearance from the US Food and Drug Administration (FDA) for soft tissue manipulation in microsurgery in April. Image credit: Gorodenkoff / Shutterstock.

Robotics company Medical Microinstruments (MMI) is looking to expand the use of its Symani surgical system.

The company announced it has completed a preclinical study evaluating its surgical robot in neurosurgical procedures.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

As part of the study, Dr Adnan Siddiqui, chief executive officer and chief medical officer of the Jacobs Institute, successfully repaired a blood vessel in the brain in an animal model. The study aimed to assess the feasibility of using Symani system for neurological conditions and obtain user feedback, from a neurosurgeon, on the system.

“Symani offered added control that allowed me to access and repair a vein just under 1 millimetre in diameter, with clips spaced 4 millimetres apart,” said Dr Siddiqui.

“It required techniques that would be extraordinarily difficult for most micro-neurosurgeons to replicate without robotic assistance, using sutures so small they are barely visible to the naked eye. Based on this excellent initial experience, I have no doubt Symani could be highly effective during a wide range of complex neurosurgical procedures with the development of additional microsurgical tools. In fact, I believe it is ready for superficial temporal to middle cerebral artery bypass surgery today.”

The Symani system allows surgeons to perform microsurgery and super-microsurgery by replicating human hand movements on a tiny scale. In April 2024, it received de novo clearance from the US Food and Drug Administration (FDA) for soft tissue manipulation in microsurgery, a technique involving intricate vessel reconnection to restore blood flow or redirect fluids during reconstruction or repair.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The market for surgical robots was worth approximately $7.2bn in 2023 and it is expected to have a strong compound annual growth rate (CAGR) of 15.7%, as per GlobalData analysis. The market growth is propelled by the incorporation of newer technologies like artificial intelligence (AI) and 5G.

GlobalData is the parent company of Clinical Trials Arena.

In December 2023, Microbot Medical partnered with Corewell Health to develop telerobotics between remote centres using the Liberty endovascular robotic surgical system. Telerobotics functionality will allow for the surgical procedure to occur without the surgeon’s presence at the concerned site.